Beacon Financial Group lowered its position in Sanofi SA (NYSE:SNY) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,079 shares of the company’s stock after selling 2,328 shares during the period. Beacon Financial Group’s holdings in Sanofi were worth $4,124,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. STA Wealth Management LLC acquired a new stake in shares of Sanofi during the 4th quarter valued at approximately $58,996,000. Motco lifted its position in shares of Sanofi by 2.2% during the 1st quarter. Motco now owns 67,326 shares of the company’s stock valued at $2,699,000 after acquiring an additional 1,474 shares during the period. Van ECK Associates Corp lifted its position in shares of Sanofi by 0.5% during the 1st quarter. Van ECK Associates Corp now owns 313,775 shares of the company’s stock valued at $12,576,000 after acquiring an additional 1,575 shares during the period. First Allied Advisory Services Inc. lifted its position in shares of Sanofi by 9.4% during the 1st quarter. First Allied Advisory Services Inc. now owns 21,370 shares of the company’s stock valued at $859,000 after acquiring an additional 1,838 shares during the period. Finally, Private Capital Group LLC lifted its position in shares of Sanofi by 271.3% during the 1st quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock valued at $103,000 after acquiring an additional 1,883 shares during the period. Hedge funds and other institutional investors own 8.46% of the company’s stock.
Shares of Sanofi traded down $0.58, reaching $41.53, during mid-day trading on Wednesday, according to Marketbeat.com. 1,396,366 shares of the company’s stock were exchanged, compared to its average volume of 2,008,813. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.70 and a quick ratio of 1.26. Sanofi SA has a 52-week low of $37.43 and a 52-week high of $50.65. The stock has a market cap of $104.51 billion, a price-to-earnings ratio of 13.31, a price-to-earnings-growth ratio of 1.97 and a beta of 0.83.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Friday, April 27th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. Sanofi had a net margin of 10.93% and a return on equity of 24.45%. The business had revenue of $7.90 billion during the quarter, compared to analysts’ expectations of $7.88 billion. During the same period last year, the company posted $1.42 EPS. The company’s revenue was down 8.7% on a year-over-year basis. equities analysts expect that Sanofi SA will post 3.21 earnings per share for the current fiscal year.
In other news, major shareholder Sanofi sold 121,601 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $309.31, for a total transaction of $37,612,405.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.00% of the company’s stock.
A number of equities research analysts have recently issued reports on SNY shares. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a research report on Monday, April 16th. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday, April 17th. ValuEngine downgraded shares of Sanofi from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 2nd. Finally, Liberum Capital upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, March 23rd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Sanofi presently has an average rating of “Hold” and a consensus price target of $49.33.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.